WO2009013545A3 - Chemical compounds - Google Patents

Chemical compounds Download PDF

Info

Publication number
WO2009013545A3
WO2009013545A3 PCT/GB2008/050617 GB2008050617W WO2009013545A3 WO 2009013545 A3 WO2009013545 A3 WO 2009013545A3 GB 2008050617 W GB2008050617 W GB 2008050617W WO 2009013545 A3 WO2009013545 A3 WO 2009013545A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemical compounds
methods
compounds
treatmentfor
cancer
Prior art date
Application number
PCT/GB2008/050617
Other languages
French (fr)
Other versions
WO2009013545A2 (en
Inventor
Stephanos Ioannidis
Michelle Lamb
Mei Su
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Stephanos Ioannidis
Michelle Lamb
Mei Su
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Stephanos Ioannidis, Michelle Lamb, Mei Su filed Critical Astrazeneca Ab
Publication of WO2009013545A2 publication Critical patent/WO2009013545A2/en
Publication of WO2009013545A3 publication Critical patent/WO2009013545A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatmentfor myeloproliferative disorders and cancer.
PCT/GB2008/050617 2007-07-26 2008-07-23 Chemical compounds WO2009013545A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95222207P 2007-07-26 2007-07-26
US60/952,222 2007-07-26

Publications (2)

Publication Number Publication Date
WO2009013545A2 WO2009013545A2 (en) 2009-01-29
WO2009013545A3 true WO2009013545A3 (en) 2009-07-02

Family

ID=40281894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050617 WO2009013545A2 (en) 2007-07-26 2008-07-23 Chemical compounds

Country Status (1)

Country Link
WO (1) WO2009013545A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5647998B2 (en) * 2009-03-13 2015-01-07 カトリーケ ユニバーシテイト ルーヴェン、ケー．ユー． ルーヴェン アール アンド ディー Thiazolopyrimidine modulators as immunosuppressants
UY33181A (en) * 2010-01-14 2011-08-31 Sanofi Aventis OXAZOLOPIRIMIDINE 2,5-SUBSTITUTED DERIVATIVES.
KR101483215B1 (en) * 2010-01-29 2015-01-16 한미약품 주식회사 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases
US20130317045A1 (en) * 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2013113715A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
EA201491667A1 (en) 2012-03-13 2015-03-31 Басф Се FUNGICIDE PYRIMIDINE COMPOUNDS
CN103242341B (en) * 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 Thieno-2,4 substituted pyrimidines compounds and pharmaceutical composition thereof and application
CN105722833A (en) 2013-09-16 2016-06-29 巴斯夫欧洲公司 Fungicidal pyrimidine compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
DK3186242T3 (en) 2014-08-29 2021-12-20 Tes Pharma S R L ALFA-AMINO-BETA-CARBOXYMUCONSIDE-SEMIALDEHYDE-DECARBOXYLASE INHIBITORS
CN110573518A (en) 2017-01-26 2019-12-13 尤拉·S·赞特里佐斯 Substituted bicyclic pyrimidinyl compounds, compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050065A2 (en) * 2000-12-21 2002-06-27 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2005049033A1 (en) * 2003-11-17 2005-06-02 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosyne kinases
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050065A2 (en) * 2000-12-21 2002-06-27 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2005049033A1 (en) * 2003-11-17 2005-06-02 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosyne kinases
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
WO2009013545A2 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
WO2009016410A3 (en) Chemical compounds 831
WO2009013545A3 (en) Chemical compounds
WO2012019426A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
SI2150530T1 (en) Substituted sulfonamide derivatives
MX2010013682A (en) Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders.
EA201001205A1 (en) COMPOUNDS CONTAINING CYCLOBUTOXY GROUP
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2008013838A3 (en) Pyridizinone derivatives
WO2012019430A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
MX2011011661A (en) Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750.
WO2009156462A3 (en) Organic compounds
WO2007135527A3 (en) Benzimidazolyl compounds
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
WO2013004995A8 (en) Pyrimidinone compounds and their use
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2010129918A8 (en) Triptolide prodrugs
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2012008328A (en) Pyrazine derivatives.
WO2013040227A3 (en) Therapeutic compounds
TW200738627A (en) Trialkylsilyl-indoles
WO2008131946A3 (en) Substituted amide derivatives
EA201001855A1 (en) COMPOUNDS CONTAINING CYCLOBUTOXY GROUP

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788592

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08788592

Country of ref document: EP

Kind code of ref document: A2